The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2024 | CAR T-cell therapy in lenalidomide-refractory multiple myeloma
In this video, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, briefly discusses the possibility of using CAR T-cell therapy in lenalidomide-refractory patients with multiple myeloma (MM). As more patients become triple-class exposed and lenalidomide-refractory, data from the CARTITUDE-4 trial (NCT04181827) suggests that this patient population may benefit significantly from CAR-T therapy. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Consulting or advisory role: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Travel support: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene; Research Funding: GlaxoSmithKline, Sanofi, Takeda, Amgen, Novartis, Janssen, Bristol Myers Squibb/Celgene.
